Cargando…
PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers (‘PD-Lomas’) is driving the clinical research st...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325162/ https://www.ncbi.nlm.nih.gov/pubmed/30413824 http://dx.doi.org/10.1038/s41416-018-0294-4 |